title: Basic and clinical research in polyomavirus nephropathy.
abstract: Over the last decade, polyomavirus nephropathy (PVN) has emerged as an important cause of renal allograft dysfunction and graft loss. PVN occurs with a prevalence of 1%-8% in renal transplant recipients and is most commonly reported within the first 12 months posttransplant. The human polyomavirus, BK virus, is thought to be the primary etiologic agent of PVN. Risk factors for PVN are not well defined and are most likely a result of a complex interaction between multiple donor and recipient factors. Definitive diagnosis of PVN is made through histological assessment of a renal allograft biopsy. Recent studies have also evaluated noninvasive urine and serum markers for screening of BK virus replication and as adjunct tools in PVN diagnosis and monitoring. The principal treatment for PVN is immunosuppression reduction, but this must be balanced against the risks of rejection. If rejection occurs concurrently with PVN, a brief increase in immunosuppression to treat the rejection episode followed by a subsequent reduction in immunosuppression is recommended. No antiviral treatments for PVN have been approved by the Food and Drug Administration. Although the antiviral drug cidofovir has shown in vitro activity against murine polyomaviruses, and has been effective in some patients, it is associated with significant nephrotoxicity. Small series of patients treated with leflunomide and intravenous immune globulin therapy for PVN have also recently been reported. Retransplantation after graft loss due to PVN is feasible, but experience is limited. Current research is focusing on identifying PVN risk factors, refining screening, diagnostic and monitoring methods, and developing therapy for prophylaxis and treatment of PVN with the goals of decreasing the prevalence of PVN and improving allograft outcomes in renal transplant recipients diagnosed with PVN. This review will present recent advances in basic and clinical research related to PVN and renal transplantation.
authors.affiliation: Division of Transplantation, University of Cincinnati, 231 Albert Sabin Way, Cincinnati, OH 45267-0558, USA. Jennifer.trofe@uc.edu
authors.forename: Jennifer
authors.initials: J
authors.lastname: Trofe
authors.forename: Jennifer
authors.initials: J
authors.lastname: Gordon
authors.forename: Prabir
authors.initials: P
authors.lastname: Roy-Chaudhury
authors.forename: Igor
authors.initials: I
authors.lastname: Koralnik
authors.forename: Walter
authors.initials: W
authors.lastname: Atwood
authors.forename: Sylvia
authors.initials: S
authors.lastname: Eash
authors.forename: Rita R
authors.initials: RR
authors.lastname: Alloway
authors.forename: Kamel
authors.initials: K
authors.lastname: Khalili
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: E Steve
authors.initials: ES
authors.lastname: Woodle
mesh_terms: D006801:Humans; D007674:Kidney Diseases / Q000821:virology*; D016030:Kidney Transplantation / Q000009:adverse effects*; D027601:Polyomavirus Infections / Q000150:complications* / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D015995:Prevalence; D011315:Preventive Medicine / Q000379:methods; D012086:Reoperation